Inhibrx Biosciences, Inc. Cash Flow Conversion Efficiency
Inhibrx Biosciences, Inc. cash flow conversion efficiency. Based on the latest financial reports, Inhibrx Biosciences, Inc. (INBX) has a cash flow conversion efficiency ratio of 1.808x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.03 Million) by net assets ($-21.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Inhibrx Biosciences, Inc. (2016–2025)
Cash flow conversion efficiency of Inhibrx Biosciences, Inc. from 2016 to 2025. This chart illustrates how Inhibrx Biosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View INBX stock price and chart for real-time trading data and today's change.
Inhibrx Biosciences, Inc. Cash Flow Conversion Ratio Explained
Inhibrx Biosciences, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Inhibrx Biosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inhibrx Biosciences, Inc. ranked by their cash flow conversion efficiency. Also see Inhibrx Biosciences, Inc. (INBX) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AS LHV GROUP EO -10
F:ASU0
|
-1.381x |
|
Sdiptech AB (publ)
ST:SDIP-B
|
0.029x |
|
Integra LifeSciences Holdings
NASDAQ:IART
|
0.009x |
|
Ningbo Cixing
SHE:300307
|
-0.014x |
|
Paras Defence and Space Technologies Limited
NSE:PARAS
|
-0.019x |
|
Meren Energy
ST:MER
|
0.166x |
|
Harrow Health Inc
NASDAQ:HROW
|
-0.657x |
|
Sino Wealth Electronic Ltd
SHE:300327
|
0.034x |
Annual Cash Flow Conversion Efficiency for Inhibrx Biosciences, Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Inhibrx Biosciences, Inc. from 2016 to 2025. Review INBX FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.99 Million | $-129.79 Million | -16.238x | -1015.79% |
| 2024-12-31 | $133.58 Million | $-194.41 Million | -1.455x | +67.25% |
| 2023-12-31 | $43.50 Million | $-193.31 Million | -4.444x | -123.75% |
| 2022-12-31 | $58.06 Million | $-115.30 Million | -1.986x | -29.52% |
| 2021-12-31 | $52.38 Million | $-80.32 Million | -1.533x | -141.26% |
| 2020-12-31 | $75.47 Million | $-47.97 Million | -0.636x | -285.38% |
| 2019-12-31 | $-93.57 Million | $-32.08 Million | 0.343x | -14.42% |
| 2018-12-31 | $-57.64 Million | $-23.09 Million | 0.401x | -52.10% |
| 2017-12-31 | $-22.42 Million | $-18.75 Million | 0.836x | +105.72% |
| 2016-12-31 | $1.24 Million | $-18.11 Million | -14.615x | -- |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-bas… Read more